Enterprise Value

44.16M

Cash

12.61M

Avg Qtr Burn

-6.76M

Short % of Float

4.99%

Insider Ownership

64.47%

Institutional Own.

4.45%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TTP399 (GLP-1R agonists) Details
Type 1 diabetes, Diabetes

Phase 3

Initiation

HPP737 (PDE4 inhibitor) Details
Psoriasis, Skin disease/disorder

Phase 2

Update

TTP399 (GLP-1R agonists) Details
Diabetes, Type 2 diabetes

Phase 2

Initiation

TTP273 (Oral GLP-1R) Details
Diabetes, Type 2 diabetes, Cystic fibrosis

Phase 1/2

Update

TTP488 (Azeliragon) (RAGE) Details
Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder

Failed

Discontinued